To date, only symptomatic treatments have been approved for AD, including acetylcholinesterase inhibitors (AChEIs) such as tacrine, donepezil, galantamine, and rivastigmine, in addition to an N-methyl-D-aspartate receptor antagonist, memantine [4]. This evidence concerns the gene ACHE and Alzheimer disease.